In vitro sequence-dependent synergistic effect of suramin and camptothecin

R. Lopez, G. J. Peters, E. Smitskamp-Wilms, J. A. Virizuela, J. van Ark-Otte, H. M. Pinedo, G. Giaccone

Research output: Contribution to journalArticle

Abstract

Suramin, a hexasulphonated naphthylurea with activity in prostatic cancer, possesses a wide variety of antitumour mechanisms of action, one of which is the inhibition of topoisomerase II. In this in vitro study, suramin was combined with the topoisomerase I inhibitor, camptothecin. Several suramin concentrations (0.2-3000 μM) were combined with camptothecin (0.4 pM-20 μM) in MCF-7 and PC3 human cancer cell line cultures. In addition, we studied the topoisomerase II and I gene expression by northern blot analysis, and the cell cycle distribution by flow cytometry, after exposure to suramin. While there was only an additive effect when suramin and camptothecin were added simultaneously, a remarkable synergism was obtained when camptothecin was added after a 3-day exposure to suramin. Topoisomerase II and I gene expression and the number of cells in S phase were significantly reduced after exposure to suramin. In conclusion, interaction of suramin with camptothecin is schedule-dependent can be synergistic. These findings might help in identifying optimal combinations of suramin or other topoisomerase II inhibitors, with topoisomerase I inhibitors.

Original languageEnglish (US)
Pages (from-to)1670-1674
Number of pages5
JournalEuropean Journal of Cancer
Volume30
Issue number11
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Suramin
Camptothecin
Type II DNA Topoisomerase
Topoisomerase I Inhibitors
Type I DNA Topoisomerase
Topoisomerase II Inhibitors
Gene Expression
In Vitro Techniques
S Phase
Northern Blotting
Prostatic Neoplasms
Appointments and Schedules
Cell Cycle
Flow Cytometry
Cell Culture Techniques
Cell Count
Cell Line

Keywords

  • camptothecin
  • drug combination
  • suramin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Lopez, R., Peters, G. J., Smitskamp-Wilms, E., Virizuela, J. A., van Ark-Otte, J., Pinedo, H. M., & Giaccone, G. (1994). In vitro sequence-dependent synergistic effect of suramin and camptothecin. European Journal of Cancer, 30(11), 1670-1674. https://doi.org/10.1016/0959-8049(94)00321-U

In vitro sequence-dependent synergistic effect of suramin and camptothecin. / Lopez, R.; Peters, G. J.; Smitskamp-Wilms, E.; Virizuela, J. A.; van Ark-Otte, J.; Pinedo, H. M.; Giaccone, G.

In: European Journal of Cancer, Vol. 30, No. 11, 1994, p. 1670-1674.

Research output: Contribution to journalArticle

Lopez, R, Peters, GJ, Smitskamp-Wilms, E, Virizuela, JA, van Ark-Otte, J, Pinedo, HM & Giaccone, G 1994, 'In vitro sequence-dependent synergistic effect of suramin and camptothecin', European Journal of Cancer, vol. 30, no. 11, pp. 1670-1674. https://doi.org/10.1016/0959-8049(94)00321-U
Lopez R, Peters GJ, Smitskamp-Wilms E, Virizuela JA, van Ark-Otte J, Pinedo HM et al. In vitro sequence-dependent synergistic effect of suramin and camptothecin. European Journal of Cancer. 1994;30(11):1670-1674. https://doi.org/10.1016/0959-8049(94)00321-U
Lopez, R. ; Peters, G. J. ; Smitskamp-Wilms, E. ; Virizuela, J. A. ; van Ark-Otte, J. ; Pinedo, H. M. ; Giaccone, G. / In vitro sequence-dependent synergistic effect of suramin and camptothecin. In: European Journal of Cancer. 1994 ; Vol. 30, No. 11. pp. 1670-1674.
@article{2914b8f8acee4c9fb53606f5bba9924b,
title = "In vitro sequence-dependent synergistic effect of suramin and camptothecin",
abstract = "Suramin, a hexasulphonated naphthylurea with activity in prostatic cancer, possesses a wide variety of antitumour mechanisms of action, one of which is the inhibition of topoisomerase II. In this in vitro study, suramin was combined with the topoisomerase I inhibitor, camptothecin. Several suramin concentrations (0.2-3000 μM) were combined with camptothecin (0.4 pM-20 μM) in MCF-7 and PC3 human cancer cell line cultures. In addition, we studied the topoisomerase II and I gene expression by northern blot analysis, and the cell cycle distribution by flow cytometry, after exposure to suramin. While there was only an additive effect when suramin and camptothecin were added simultaneously, a remarkable synergism was obtained when camptothecin was added after a 3-day exposure to suramin. Topoisomerase II and I gene expression and the number of cells in S phase were significantly reduced after exposure to suramin. In conclusion, interaction of suramin with camptothecin is schedule-dependent can be synergistic. These findings might help in identifying optimal combinations of suramin or other topoisomerase II inhibitors, with topoisomerase I inhibitors.",
keywords = "camptothecin, drug combination, suramin",
author = "R. Lopez and Peters, {G. J.} and E. Smitskamp-Wilms and Virizuela, {J. A.} and {van Ark-Otte}, J. and Pinedo, {H. M.} and G. Giaccone",
year = "1994",
doi = "10.1016/0959-8049(94)00321-U",
language = "English (US)",
volume = "30",
pages = "1670--1674",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - In vitro sequence-dependent synergistic effect of suramin and camptothecin

AU - Lopez, R.

AU - Peters, G. J.

AU - Smitskamp-Wilms, E.

AU - Virizuela, J. A.

AU - van Ark-Otte, J.

AU - Pinedo, H. M.

AU - Giaccone, G.

PY - 1994

Y1 - 1994

N2 - Suramin, a hexasulphonated naphthylurea with activity in prostatic cancer, possesses a wide variety of antitumour mechanisms of action, one of which is the inhibition of topoisomerase II. In this in vitro study, suramin was combined with the topoisomerase I inhibitor, camptothecin. Several suramin concentrations (0.2-3000 μM) were combined with camptothecin (0.4 pM-20 μM) in MCF-7 and PC3 human cancer cell line cultures. In addition, we studied the topoisomerase II and I gene expression by northern blot analysis, and the cell cycle distribution by flow cytometry, after exposure to suramin. While there was only an additive effect when suramin and camptothecin were added simultaneously, a remarkable synergism was obtained when camptothecin was added after a 3-day exposure to suramin. Topoisomerase II and I gene expression and the number of cells in S phase were significantly reduced after exposure to suramin. In conclusion, interaction of suramin with camptothecin is schedule-dependent can be synergistic. These findings might help in identifying optimal combinations of suramin or other topoisomerase II inhibitors, with topoisomerase I inhibitors.

AB - Suramin, a hexasulphonated naphthylurea with activity in prostatic cancer, possesses a wide variety of antitumour mechanisms of action, one of which is the inhibition of topoisomerase II. In this in vitro study, suramin was combined with the topoisomerase I inhibitor, camptothecin. Several suramin concentrations (0.2-3000 μM) were combined with camptothecin (0.4 pM-20 μM) in MCF-7 and PC3 human cancer cell line cultures. In addition, we studied the topoisomerase II and I gene expression by northern blot analysis, and the cell cycle distribution by flow cytometry, after exposure to suramin. While there was only an additive effect when suramin and camptothecin were added simultaneously, a remarkable synergism was obtained when camptothecin was added after a 3-day exposure to suramin. Topoisomerase II and I gene expression and the number of cells in S phase were significantly reduced after exposure to suramin. In conclusion, interaction of suramin with camptothecin is schedule-dependent can be synergistic. These findings might help in identifying optimal combinations of suramin or other topoisomerase II inhibitors, with topoisomerase I inhibitors.

KW - camptothecin

KW - drug combination

KW - suramin

UR - http://www.scopus.com/inward/record.url?scp=0028150701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028150701&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)00321-U

DO - 10.1016/0959-8049(94)00321-U

M3 - Article

C2 - 7833142

AN - SCOPUS:0028150701

VL - 30

SP - 1670

EP - 1674

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -